All In Biotech

Drug Trial Radar · NCT01868997

Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease

A Multicenter, Double-Masked, Placebo-Controlled, Efficacy And Safety Study Of RV 001, An Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), Administered Every 3 Weeks (q3W) By Intravenous (IV) Infusion In Patients Suffering From Active Thyroid Eye Disease (TED)

Last checked: Nov 19, 2026Latest source record: Dec 17, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

88

Actual

Start

Jul 2013

Primary completion

Mar 2016

Study completion Feb 22, 2017

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Jun 5, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to investigate the efficacy, safety, and tolerability of RV 001 (teprotumumab), a fully human anti-IGF1R antibody, administered q3W for 6 months, in comparison to placebo, in the treatment of participants suffering from active TED. "Funding Source - FDA OOPD"

Conditions

  • Thyroid Associated Ophthalmopathies
  • Thyroid-Associated Ophthalmopathy

Interventions

  • teprotumumabDrug

  • normal salineDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Responder Status at Week 24Time frame: Week 24

Locations

15 sites in 4 countries. Site status is shown where the registry gives one.

  • Jules Stein Eye Institute at UCLA

    Los Angeles, California

  • University of Denver

    Aurora, Colorado

  • Emory University Department of Ophthalmology

    Atlanta, Georgia

  • University of Iowa Hospitals and Clinics, Department of Ophthalmology

    Iowa City, Iowa

  • Kellogg Eye Center at University of Michigan

    Ann Arbor, Michigan

  • Washington University Department of Ophthalmology

    St Louis, Missouri

  • University of Nebraska Medical Center Department of Ophthalmology

    Omaha, Nebraska

  • Casey Eye Institute at Oregon Health and Science University

    Portland, Oregon

  • Hamilton Eye Institute at University of Tennessee

    Memphis, Tennessee

  • Eye Wellness Center

    Houston, Texas

  • Medical College of Wisconsin, The Eye Institute

    Milwaukee, Wisconsin

  • Johannes Gutenberg University Medical Center

    Mainz, Germany

  • Fondazione Ca' Granda Ospedale Policlinico Graves GO Center

    Milan, Italy

  • University of Pisa, Azienda Ospedaliera

    Pisa, Italy

  • Moorfields Eye Hospital

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.